New Urology Products & Services
Bloomington, IN-Cook Medical has developed the BIGopsy biopsy forceps that capture specimens of sufficient size to produce accurate biopsy results without need for additional samples. The forceps' oversized jaw design and patented backloading handle obtain specimens up to four times larger than those available with traditional forceps, and the 2.4F sheath offers greater flow than do standard 3F sheaths.
Backloading biopsy forceps capture larger specimens
For more information, visit http://www.cookmedical.com/.
Streetsboro, OH-The Evolve SLV from ForTec Medical, Inc., uses a 980-nm wavelength laser for efficient management of the symptoms of BPH. The procedure can be performed in the office in less than 2 hours with excellent hemostasis. The wavelength provides high absorption in water and hemoglobin for effective cutting and coagulation with minimal tissue damage, side effects, discomfort, and inconvenience to patients, according to ForTec. Leasing arrangements and staff training are available through the manufacturer.
For more information, visit http://www.fortecmedical.com/.
Point-of-care immunoassay gives PSA, T results in minutes
For more information, visit http://www.qualigeninc.com/.
Antiseptic swab is approved for injection site prep
For more information, visit http://www.pdipdi.com/.
Chairless uroflowmetry system measures, tracks easily
Bothell, WA-Verathon's FloPoint Elite Uroflowmetry System measures and records voided volume, average and peak flows, time to peak flow, and flow and void times accurately and without need for beakers of urine. The lightweight, portable unit installs in seconds on a standard toilet, reassuring patients and minimizing cleanup. The digital wireless unit provides readouts, allows online calibration, and reports results in print or electronic medical record formats via the ScanPoint System. CPT Code 51741 is Medicare-approved.
For more information, visit http://www.verathon.com/.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
